BIOA.F Stock Overview
A development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Bioasis Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0002 |
| 52 Week High | US$0.013 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 19,900.00% |
| 3 Month Change | 19,900.00% |
| 1 Year Change | -95.00% |
| 3 Year Change | -99.92% |
| 5 Year Change | -99.89% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOA.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 100.0% | 1.9% | 0.7% |
| 1Y | -95.0% | -6.6% | 23.9% |
Return vs Industry: BIOA.F underperformed the US Biotechs industry which returned -7.2% over the past year.
Return vs Market: BIOA.F underperformed the US Market which returned 24.4% over the past year.
Price Volatility
| BIOA.F volatility | |
|---|---|
| BIOA.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BIOA.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine BIOA.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Deborah Rathjen | www.bioasis.us |
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company’s in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007).
Bioasis Technologies Inc. Fundamentals Summary
| BIOA.F fundamental statistics | |
|---|---|
| Market cap | US$15.88k |
| Earnings (TTM) | -US$2.01m |
| Revenue (TTM) | US$188.17k |
0.0x
P/S Ratio0.0x
P/E RatioIs BIOA.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOA.F income statement (TTM) | |
|---|---|
| Revenue | CA$269.38k |
| Cost of Revenue | CA$968.85k |
| Gross Profit | -CA$699.47k |
| Other Expenses | CA$2.18m |
| Earnings | -CA$2.88m |
Last Reported Earnings
Nov 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did BIOA.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 06:24 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2022/11/30 |
| Annual Earnings | 2022/02/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bioasis Technologies Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathaniel Calloway | Edison Investment Research |
| William Gregozeski | Greenridge Global LLC |
| John Vandermosten | Zacks Small-Cap Research |